Ascendum Capital is a private equity firm founded in 2020 and based in Hong Kong, China. The firm specializes in healthcare investments, targeting companies involved in innovative MedTech, biotechnology, and other technology sectors related to healthcare. Ascendum Capital aims to accelerate the research and development as well as the commercialization of leading healthcare technologies. Additionally, the firm supports healthcare companies in their expansion efforts or acquisitions, with a particular emphasis on the Chinese market.
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Valgen Medtech
Series B in 2021
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
EndoWays
Acquisition in 2021
EndoWays is a robotics company based in Tel Aviv, Israel, established in 2017. It specializes in the development of self-propelling micro-catheters designed to navigate complex and tortuous blood vessels. The company's innovative software platform enhances the capabilities of interventional radiologists and cardiologists, allowing them to perform intricate procedures in neurovascular, peripheral, and cardiac contexts. By utilizing a fully disposable robotic system, EndoWays aims to improve procedural efficiency, reduce operation time, and minimize radiation exposure for both patients and medical staff.
Broncus Medical
Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.